The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C10 | Lipid modifying agents | |
| 3 | C10A | Lipid modifying agents, plain | |
| 4 | C10AX | Other lipid modifying agents | |
| 5 | C10AX10 | Alipogene tiparvovec |
| Active Ingredient | Description | |
|---|---|---|
| Alipogene tiparvovec |
Alipogene tiparvovec contains the human lipoprotein lipase (LPL) gene variant LPLS447X in a vector. The human LPL gene variant LPLS447X in an adeno-associated virus serotype 1 (AAV1) vector intended to target the muscle. Alipogene tiparvovec is injected as a one-time series into the muscle of the lower extremities where it is taken up by myocytes. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GLYBERA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
